Kiniksa Pharmaceuticals International, plc (KNSA) stock
KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30461% above fair value
$94.23−2.10 (-2.18%)
Close on Nov 16, 2026Market cap $14.81BP/E 72.5Yield –
Kiniksa Pharmaceuticals International ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kiniksa Pharmaceuticals International's ebitda for the twelve months ending Sep 30, 2026 was $132.36M, up 233.9% year over year. For fiscal 2025 it was $78.78M. The highest annual figure on record is $78.78M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.78M | – |
| FY2024 | Dec 31, 2024 | -$43.92M | – |
| FY2023 | Dec 31, 2023 | -$22.86M | -287.7% |
| FY2022 | Dec 31, 2022 | $12.18M | – |
| FY2021 | Dec 31, 2021 | -$154.28M | – |
| FY2020 | Dec 31, 2020 | -$154.96M | – |
| FY2019 | Dec 31, 2019 | -$167.90M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $54.73M | +124.2% |
| Q2 FY2026 | Jun 30, 2026 | $27.67M | +34.8% |
| Q1 FY2026 | Mar 31, 2026 | $29.74M | +118.4% |
| Q4 FY2025 | Dec 31, 2025 | $20.24M | – |
| Q3 FY2025 | Sep 30, 2025 | $24.41M | – |
| Q2 FY2025 | Jun 30, 2025 | $20.52M | +6455.3% |
| Q1 FY2025 | Mar 31, 2025 | $13.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$18.90M | -3143.3% |
| Q3 FY2024 | Sep 30, 2024 | -$9.26M | – |
| Q2 FY2024 | Jun 30, 2024 | $313.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.08M | – |
| Q4 FY2023 | Dec 31, 2023 | $621.00K | -90.7% |
| Q3 FY2023 | Sep 30, 2023 | -$10.32M | -122.0% |
| Q2 FY2023 | Jun 30, 2023 | -$2.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.60M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.65M | – |
| Q3 FY2022 | Sep 30, 2022 | $46.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$18.72M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.66M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$30.01M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$48.97M | – |
| Q4 FY2020 | Dec 31, 2020 | -$52.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$42.57M | – |
| Q2 FY2020 | Jun 30, 2020 | -$31.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$28.79M | – |
See a number that looks wrong?